Plant Name: Kopsia albiflora
Taxonomic Information:
Plant ID: NPO1821
Plant Latin Name: Kopsia albiflora
Taxonomy Genus: Kopsia
Taxonomy Family: Apocynaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ACHE; | |
| RECQL; HSD17B1; | |
| CSNK2A1; | |
| RORC; | |
| NR1H4; | |
| ESR2; | |
| THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.512E-10 | 1.379E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.255E-08 | 6.830E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.193E-08 | 9.550E-05 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.764E-07 | 4.802E-04 | ESR2, HSD17B1, NR1H4, RORC |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.421E-07 | 5.220E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 3.222E-07 | 5.725E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.739E-07 | 1.119E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.121E-06 | 2.109E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.131E-06 | 2.109E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 3.321E-06 | 2.893E-03 | ESR2, NR1H4, RORC |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 5.840E-06 | 4.541E-03 | ESR2, NR1H4, RORC |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 9.886E-06 | 7.001E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 1.266E-05 | 8.616E-03 | ACHE, CSNK2A1, CYP19A1, CYP1A1, HSD17B1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 5.814E-11 | 8.488E-09 | HSD11B1, HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.009E-07 | 4.910E-06 | HSD17B1, CYP1A1, CYP1B1, PTGS2, CYP19A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.241E-08 | 2.366E-06 | HSD11B1, CYP1A2, CYP1A1, CYP1B1, CYP3A4, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 3.030E-06 | 7.373E-05 | AR, GSK3B, CDK6, FLT3, PTGS2, HIF1A, TP53, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 6.877E-07 | 2.510E-05 | HSD11B1, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.106E-06 | 6.150E-05 | MAOA, CYP1A2, CYP1A1, CYP1B1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.646E-05 | 2.739E-04 | HSD11B1, PKM, AKR1B10, MAOA, HSD17B1, CYP1A2, ALOX15, CYP1A1, PTGS2, CYP3A4, CYP19A1, XDH |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 1.480E-05 | 2.739E-04 | GSK3B, CDK6, CSNK2A1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.688E-05 | 2.739E-04 | PKM, FLT3, TP53, HIF1A |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 2.247E-05 | 2.982E-04 | GSK3B, ESR1, NFKB1, ESR2 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.505E-05 | 3.047E-04 | PTPN1, CSNK2A1, ACP1, PTPRF |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 2.126E-05 | 2.982E-04 | NR1H4, CYP3A4, CFTR, ABCG2 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 5.183E-05 | 4.729E-04 | GSK3B, AR, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 5.796E-05 | 4.977E-04 | ABCC1, CDK6, CYP1B1, PTGS2, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 4.530E-05 | 4.725E-04 | CDK6, PTGS2, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 9.793E-05 | 7.525E-04 | GSK3B, SYK, CSNK2A1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.050E-04 | 7.662E-04 | CDK6, PKM, SYK, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 6.156E-05 | 4.994E-04 | SYK, CSNK2A1, PTGS2, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 1.142E-04 | 7.940E-04 | PTPN1, GSK3B, NFKB1, PTPRF |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.552E-04 | 9.850E-04 | GSK3B, TP53, ESR1, HIF1A |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.990E-05 | 4.481E-04 | CYP1A2, ALOX15, CYP3A4 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.081E-03 | 5.442E-03 | GSK3B, CDK6, SYK, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 4.708E-04 | 2.749E-03 | CDK6, TP53, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 6.327E-04 | 3.299E-03 | GSK3B, SYK, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 6.327E-04 | 3.299E-03 | CDK6, TP53, NFKB1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 4.501E-04 | 2.738E-03 | CYP1A2, CYP1A1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 5.364E-04 | 3.012E-03 | MAOA, CYP1A2, CYP3A4 |
| 09130 Environmental Information Processing | 09131 Membrane transport | hsa02010 | ABC transporters | 1.412E-04 | 9.368E-04 | ABCC1, CFTR, ABCG2 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 5.153E-05 | 4.729E-04 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
